50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
QQQ   279.94 (+1.99%)
AAPL   149.84 (-1.27%)
MSFT   241.07 (+1.97%)
META   141.61 (+5.36%)
GOOGL   100.05 (+2.62%)
AMZN   118.01 (+3.15%)
TSLA   287.81 (+1.72%)
NVDA   127.36 (+2.60%)
NIO   17.33 (+0.81%)
BABA   80.99 (+4.01%)
AMD   68.36 (+1.77%)
T   15.83 (+0.64%)
MU   51.00 (+0.83%)
CGC   3.04 (+6.29%)
F   12.18 (+2.27%)
GE   64.46 (-0.02%)
DIS   99.40 (+3.70%)
AMC   7.67 (+2.95%)
PYPL   91.12 (+6.26%)
PFE   44.43 (+0.77%)
NFLX   245.20 (+9.29%)
QQQ   279.94 (+1.99%)
AAPL   149.84 (-1.27%)
MSFT   241.07 (+1.97%)
META   141.61 (+5.36%)
GOOGL   100.05 (+2.62%)
AMZN   118.01 (+3.15%)
TSLA   287.81 (+1.72%)
NVDA   127.36 (+2.60%)
NIO   17.33 (+0.81%)
BABA   80.99 (+4.01%)
AMD   68.36 (+1.77%)
T   15.83 (+0.64%)
MU   51.00 (+0.83%)
CGC   3.04 (+6.29%)
F   12.18 (+2.27%)
GE   64.46 (-0.02%)
DIS   99.40 (+3.70%)
AMC   7.67 (+2.95%)
PYPL   91.12 (+6.26%)
PFE   44.43 (+0.77%)
NFLX   245.20 (+9.29%)
QQQ   279.94 (+1.99%)
AAPL   149.84 (-1.27%)
MSFT   241.07 (+1.97%)
META   141.61 (+5.36%)
GOOGL   100.05 (+2.62%)
AMZN   118.01 (+3.15%)
TSLA   287.81 (+1.72%)
NVDA   127.36 (+2.60%)
NIO   17.33 (+0.81%)
BABA   80.99 (+4.01%)
AMD   68.36 (+1.77%)
T   15.83 (+0.64%)
MU   51.00 (+0.83%)
CGC   3.04 (+6.29%)
F   12.18 (+2.27%)
GE   64.46 (-0.02%)
DIS   99.40 (+3.70%)
AMC   7.67 (+2.95%)
PYPL   91.12 (+6.26%)
PFE   44.43 (+0.77%)
NFLX   245.20 (+9.29%)
QQQ   279.94 (+1.99%)
AAPL   149.84 (-1.27%)
MSFT   241.07 (+1.97%)
META   141.61 (+5.36%)
GOOGL   100.05 (+2.62%)
AMZN   118.01 (+3.15%)
TSLA   287.81 (+1.72%)
NVDA   127.36 (+2.60%)
NIO   17.33 (+0.81%)
BABA   80.99 (+4.01%)
AMD   68.36 (+1.77%)
T   15.83 (+0.64%)
MU   51.00 (+0.83%)
CGC   3.04 (+6.29%)
F   12.18 (+2.27%)
GE   64.46 (-0.02%)
DIS   99.40 (+3.70%)
AMC   7.67 (+2.95%)
PYPL   91.12 (+6.26%)
PFE   44.43 (+0.77%)
NFLX   245.20 (+9.29%)
NASDAQ:RVMD

Revolution Medicines - RVMD Stock Forecast, Price & News

$19.80
+0.94 (+4.98%)
(As of 09/28/2022 12:00 AM ET)
Add
Compare
Today's Range
$19.17
$20.08
50-Day Range
$17.46
$26.00
52-Week Range
$14.08
$34.16
Volume
877,128 shs
Average Volume
774,333 shs
Market Capitalization
$1.74 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$29.25

Revolution Medicines MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
47.7% Upside
$29.25 Price Target
Short Interest
Bearish
15.21% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.72
Upright™ Environmental Score
News Sentiment
0.30mentions of Revolution Medicines in the last 14 days
Based on 4 Articles This Week
Insider Trading
Acquiring Shares
$1 M Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.33) to ($3.53) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.13 out of 5 stars

Medical Sector

552nd out of 1,096 stocks

Biological Products, Except Diagnostic Industry

88th out of 172 stocks

RVMD stock logo

About Revolution Medicines (NASDAQ:RVMD) Stock

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Receive RVMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Revolution Medicines and its competitors with MarketBeat's FREE daily newsletter.

RVMD Stock News Headlines

Revolution Medicines (NASDAQ:RVMD) Shares Gap Down to $17.46
Revolution Medicines (NASDAQ:RVMD) Stock Price Down 5.9%
Revolution Medicines promotes Jack Anders to CFO
RVMD Crosses Below Key Moving Average Level
Revolution Medicines Stock Is Getting Hammered: Here's Why
See More Headlines
Receive RVMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Revolution Medicines and its competitors with MarketBeat's FREE daily newsletter.

RVMD Company Calendar

Last Earnings
8/09/2022
Today
9/28/2022
Next Earnings (Estimated)
11/09/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RVMD
Fax
N/A
Employees
188
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$29.25
High Stock Price Forecast
$37.00
Low Stock Price Forecast
$24.00
Forecasted Upside/Downside
+47.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-187,090,000.00
Net Margins
-823.65%
Pretax Margin
-823.65%

Debt

Sales & Book Value

Annual Sales
$29.39 million
Book Value
$8.18 per share

Miscellaneous

Free Float
71,211,000
Market Cap
$1.74 billion
Optionable
Not Optionable
Beta
1.68

Key Executives

  • Dr. Mark A. Goldsmith Ph.D. (Age 60)
    CEO, Pres & Chairman
    Comp: $1.01M
  • Mr. Jack AndersMr. Jack Anders (Age 45)
    Sr. VP of Fin. & Principal Accounting Officer
    Comp: $462.13k
  • Ms. Margaret A. Horn J.D. (Age 59)
    COO, Gen. Counsel & Sec.
    Comp: $773.03k
  • Dr. Stephen M. Kelsey FRC Path. (Age 61)
    FRCP, M.D., Pres of R&D
    Comp: $773.03k
  • Ms. Xiaolin WangMs. Xiaolin Wang (Age 51)
    Exec. VP of Clinical Devel.
    Comp: $582.43k
  • Dr. Martin D. Burke M.D.
    Ph.D., Co-Founder & Chairman of Scientific Advisory Board
  • Dr. Michael A. Fischbach Ph.D. (Age 41)
    Academic Co-Founder & Member of Scientific Advisory Board
  • Dr. Kevan M. Shokat Ph.D.
    Academic Co-Founder & Member of Scientific Advisory Board
  • Mr. David L. Pompliano Ph.D.
    Founding Chief Scientific Officer
  • Mr. Walter Reiher Ph.D.
    Chief Information Officer













RVMD Stock - Frequently Asked Questions

Should I buy or sell Revolution Medicines stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Revolution Medicines in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RVMD shares.
View RVMD analyst ratings
or view top-rated stocks.

What is Revolution Medicines' stock price forecast for 2022?

4 Wall Street analysts have issued 12-month price targets for Revolution Medicines' stock. Their RVMD share price forecasts range from $24.00 to $37.00. On average, they anticipate the company's share price to reach $29.25 in the next twelve months. This suggests a possible upside of 47.7% from the stock's current price.
View analysts price targets for RVMD
or view top-rated stocks among Wall Street analysts.

How have RVMD shares performed in 2022?

Revolution Medicines' stock was trading at $25.17 on January 1st, 2022. Since then, RVMD stock has decreased by 21.3% and is now trading at $19.80.
View the best growth stocks for 2022 here
.

When is Revolution Medicines' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our RVMD earnings forecast
.

How were Revolution Medicines' earnings last quarter?

Revolution Medicines, Inc. (NASDAQ:RVMD) announced its earnings results on Tuesday, August, 9th. The company reported ($0.82) earnings per share for the quarter, topping the consensus estimate of ($0.87) by $0.05. The business earned $9.12 million during the quarter, compared to analysts' expectations of $8.75 million. Revolution Medicines had a negative trailing twelve-month return on equity of 39.20% and a negative net margin of 823.65%.

What other stocks do shareholders of Revolution Medicines own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Revolution Medicines investors own include Alector (ALEC), Editas Medicine (EDIT), Homology Medicines (FIXX), Gossamer Bio (GOSS), Livongo Health (LVGO), Sorrento Therapeutics (SRNE), Black Diamond Therapeutics (BDTX), Beam Therapeutics (BEAM), CrowdStrike (CRWD) and Precision BioSciences (DTIL).

When did Revolution Medicines IPO?

(RVMD) raised $150 million in an initial public offering on Thursday, February 13th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen, SVB Leerink and Guggenheim Securities served as the underwriters for the IPO.

What is Revolution Medicines' stock symbol?

Revolution Medicines trades on the NASDAQ under the ticker symbol "RVMD."

Who are Revolution Medicines' major shareholders?

Revolution Medicines' stock is owned by a number of retail and institutional investors. Top institutional shareholders include TRV GP Iii LLC (6.87%), Column Group LLC (5.92%), State Street Corp (3.53%), Price T Rowe Associates Inc. MD (2.55%), JPMorgan Chase & Co. (2.50%) and Goldman Sachs Group Inc. (1.01%). Insiders that own company stock include Anthony W Boor, Barbara Weber, Elizabeth M Anderson, Jack Anders, James E Flynn, Jeanna Steele, Lorence H Kim, Margaret A Horn, Mark A Goldsmith, Peter Svennilson, Rock Ventures Ii LP Third, Rock Ventures Iii LP Third, Stephen Michael Kelsey, Thilo Schroeder, Vincent A Miller and Xiaolin Wang.
View institutional ownership trends
.

How do I buy shares of Revolution Medicines?

Shares of RVMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Revolution Medicines' stock price today?

One share of RVMD stock can currently be purchased for approximately $19.80.

How much money does Revolution Medicines make?

Revolution Medicines (NASDAQ:RVMD) has a market capitalization of $1.74 billion and generates $29.39 million in revenue each year. The company earns $-187,090,000.00 in net income (profit) each year or ($3.03) on an earnings per share basis.

How many employees does Revolution Medicines have?

The company employs 188 workers across the globe.

How can I contact Revolution Medicines?

Revolution Medicines' mailing address is 700 Saginaw Drive, Redwood City CA, 94063. The official website for the company is www.revmed.com. The company can be reached via phone at 650-481-6801 or via email at ir@revmed.com.

This page (NASDAQ:RVMD) was last updated on 9/28/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.